cjc-1295 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-06. Numbers and descriptions here follow the published literature rather than marketing material.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
== Function == Ceruloplasmin (CP) is an enzyme (EC 1.16.3.1) synthesized in the liver containing 6 atoms of copper in its structure. Ceruloplasmin carries more than 95% of the total copper in healthy human plasma. The rest is accounted for by macroglobulins. Ceruloplasmin exhibits a copper-dependent oxidase activity, which is associated with possible oxidation of Fe2+ (ferrous iron) into Fe3+ (ferric iron), therefore assisting in its transport in the plasma in association with transferrin, which can carry iron only in the ferric state. The molecular weight of human ceruloplasmin is reported to be 151kDa. Mutations have been known to disrupt the binding of copper to CP and will disrupt iron metabolism and cause an iron overload. Ceruloplasmin is a relatively large enzyme (~10 nm); the larger size prevents the bound copper from being lost in a person's urine during transport.
== Screening == There is debate as to the benefits of widespread screening measures for coeliac disease. In 2017, the United States Preventive Services Task Force published a report which found insufficient evidence to make a recommendation regarding screening for coeliac disease in those without symptoms. Due to the lack of evidence that screening for coeliac disease in those without symptoms, clinical guidelines advise testing people based on symptoms and selective screening for certain populations at a higher risk of developing coeliac disease.
Restriction Fragment Length Polymorphism (RFLP) is a technique for analyzing the variable lengths of DNA fragments that result from digesting a DNA sample with a restriction endonuclease. The restriction endonuclease cuts DNA at a specific sequence pattern known as a restriction endonuclease recognition site. The presence or absence of certain recognition sites in a DNA sample generates variable lengths of DNA fragments, which are separated using gel electrophoresis. They are then hybridized with DNA probes that bind to a complementary DNA sequence in the sample. In polymerase chain reaction (PCR) analysis, millions of exact copies of DNA from a biological sample are made. It used to amplify a specific region of a DNA strand (the DNA target). Most PCR methods typically amplify DNA fragments of between 0.1 and 10 kilo base pairs (kb), although some techniques allow amplification of fragments up to 40 kb in size. PCR also uses heat to separate the DNA strands. DNA fragmented during apoptosis, of a size from 1 to 20 nucleosomes, can be selectively isolated from the cells fixed in the denaturing fixative ethanol
=== Period 1: "Classical" early style (circa 300–400 CE) === The earliest paintings at Kizil belong to a "Classical" stage. Their style is very elegant and "painterly", with sophisticated shading of the bodies to express sculptural volume. The lines are refined and subtle, the colors blend softly. This style is also characteristically Indian, and may be related to Gandhara or Kashmir. This early style is exemplified by the Cave of the Hippocampi (Cave 118), and may form a distinctive school. This contrasts with the style of the following stage, as seen in the panels in the cella of the Cave of the Statues, such as the "Cowherd Nanda", which is much bolder, using intense colors (but still browns, greens and oranges only), thicker lines and simpler patterns.
Astatine-210 and most of the lighter isotopes exhibit beta plus decay (positron emission), astatine-217 and heavier isotopes except astatine-218 exhibit beta minus decay, while astatine-211 undergoes electron capture. The most stable isotope is astatine-210, which has a half-life of 8.1 hours. The primary decay mode is beta plus, to the relatively long-lived (in comparison to astatine isotopes) alpha emitter polonium-210. In total, only five isotopes have half-lives exceeding one hour (astatine-207 to -211). The least stable ground state isotope is astatine-213, with a half-life of 125 nanoseconds. It undergoes alpha decay to the extremely long-lived bismuth-209. Astatine has 24 known nuclear isomers, which are nuclei with one or more nucleons (protons or neutrons) in an excited state. A nuclear isomer may also be called a "meta-state", meaning the system has more internal energy than the "ground state" (the state with the lowest possible internal energy), making the former likely to decay into the latter. There may be more than one isomer for each isotope. The most stable of these nuclear isomers is astatine-202m1, which has a half-life of about 3 minutes, longer than those of all the ground states bar those of isotopes 203–211 and 220. The least stable is astatine-213m1; its half-life of 110 nanoseconds is shorter than 125 nanoseconds for astatine-213, the shortest-lived ground state.
Sources: en.wikipedia.org
=== Digestive === The apelin receptor is expressed in several cell types of the gastro-intestinal tract : stomach enterochromaffine-like cells; unknown cells of endocrine pancreas, colon epithelial cells. In stomach, activation of receptors on enterochromaffine-like cells by apelin secreted by parietal cells can inhibit histamine release by enterochromaffine-like cells, which in turn decreases acid secretion by parietal cells. In pancreas, apelin inhibits the insulin secretion induced by glucose. This inhibition reveals the functional interdependency between apelin signalling and insulin signalling observed at the adipocyte level where insulin stimulate apelin production. Recently, receptor expression was also detected in skeletic muscle cells. Its activation is involved in glucose uptake and participates in the control of glucose blood levels glycemia.
The ascent led through forests of chestnut, laurels, and heaths, and onto higher, barren volcanic plains such as Llano del Retama, where vegetation diminished and only shrubs and wildlife remained. At Estancia de los Ingleses, a traditional rest point at about 8,000 feet (2,400 m), the group endured a cold, windy night before continuing the climb at 3 a.m. on 22 June 1799. They crossed the Malpays, an area of broken lava and little vegetation, and reached the summit at 8 a.m. At the peak, the party observed the structure of the volcano, measured ground temperatures, and collected air samples. The elliptical crater showed no recent eruptions inside, but the volcano remained active, with recent lava flows and geothermal activity. The summit provided panoramic views of the surrounding islands and the diverse ecological zones descending from the peak, which Humboldt recorded in a sketch. He noted five distinct vegetation zones, from grasses at the summit to cultivated tropical and temperate plants near the coast. The descent took the party back through the varying ecological regions. Humboldt made broader geological observations, considering questions about the structure and origins of volcanoes and the laws governing geological phenomena. The round trip from La Orotava to the summit and back lasted twenty-one hours. The Pizarro’s departure was delayed until 24 or 25 June 1799 due to the presence of an English squadron, allowing Humboldt and Bonpland additional time to explore the island’s surroundings.
Role of skin in locomotion describes how the integumentary system is involved in locomotion. Typically the integumentary system can be thought of as skin, however the integumentary system also includes the segmented exoskeleton in arthropods and feathers of birds. The primary role of the integumentary system is to provide protection for the body. However, the structure of the skin has evolved to aid animals in their different modes of locomotion. Soft bodied animals such as starfish rely on the arrangement of the fibers in their tube feet for movement. Eels, snakes, and fish use their skin like an external tendon to generate the propulsive forces need for undulatory locomotion. Vertebrates that fly, glide, and parachute also have a characteristic fiber arrangements of their flight membranes that allows for the skin to maintain its structural integrity during the stress and strain experienced during flight.
This formula was developed by Levey et al. The 2009 CKD-EPI formula was suggested to improve cardiovascular risk prediction over the MDRD Study formula in a middle-age population. The 2021 CKD-EPI formula does not include a race coefficient (see discussion below). The 2021 CKD-EPI equation is:
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.